Introduction
Gene transfer to the salivary glands as a novel means of delivering protein-based therapeutics to the oral cavity has generated considerable interest over the past decade. With the ever-expanding armamentarium of anti-microbial and anti-biofilm peptides being developed in the dental research field, the potential applications of sustained, even regulatable 1 transgene expression in the salivary gland to the practice of dental medicine are considerable. 2 Realizing the full potential of this intriguing approach will require the development of gene transfer vectors that either achieve extremely prolonged duration of expression or can be periodically readministered.
Heretofore, gene transfer to the salivary gland has been accomplished by means of viral vector systems, including Adenovirus 3 (Ad) and Adeno-associated virus. 4 More recently, this approach has moved forward to a human clinical trial 5 aimed at establishing a gene therapy treatment for radiation-induced xerostomia. 6 Viral vectors have clearly proven the principle that gene transfer to the salivary glands has the potential to transform many facets of oral medicine, but viral vector technology has drawbacks. 7 Despite significant progress, viral vectors elicit host immune responses, [8] [9] [10] can pose onocogenic risks 11, 12 and cannot achieve life-long expression in vivo.
Non-viral vectors overcome many of the limitations of viral vector system, and recent advances in plasmid gene transfer vectors have decreased immunogenicity and enhanced the duration of expression. However, delivery of non-viral vectors to target tissues, such as the salivary gland, is extremely challenging as eukaryotic cell membranes typically exclude genetic material. Techniques such as hydrodynamic gene delivery, 13 various nanoparticles and electroporation [14] [15] [16] have shown proof of the principle in selective applications, but have not been used successfully to achieve gene transfer to the salivary gland.
Ultrasound-assisted gene transfer (UAGT) has been proposed as a gene transfer technique on the basis of the concept of 'sonoporation'. [17] [18] [19] This strategy uses microbubbles of various compositions, originally developed as ultrasound contrast agents. In the presence of relatively high mechanical index ultrasound energy, these microbubbles oscillate at high frequency and rapidly collapse creating inertial cavitation in a liquid medium. If this ultrasound-mediated microbubble destruction occurs in proximity to a cell membrane, disruption of the lipid bilayer can occur allowing large macromolecules, such as plasmid vectors, to enter the cell. UAGT has been shown in numerous experimental paradigms, but has been difficult to apply to the in vivo situation. In this study, we explored whether UAGT could accomplish gene transfer after administration of microbubbles/plasmid solution to the intraductal compartment of the submandibular salivary gland of the mouse.
Results

UAGT enables non-viral gene transfer to the mouse submandibular gland
In Figure 1 , anatomical localization of Luciferase (Luc) transgene expression is shown for the three highestexpressing UAGT animals 21 days post-treatment. Following unilateral UAGT via the right submandibular duct, Luc activity was localized unilaterally in the anatomical region corresponding to the salivary gland. Intensity of gene expression in these three animals varied across a B10-fold range.
Efficacy of UAGT is highly dependent upon microbubble concentration
When our plasmid vector was delivered in 50 ml of freshly prepared, undiluted Definity microbubbles (Lantheus Medical Imaging, North Billerica, MA, USA), we observed the absence of or extremely poor gene transfer that lasted for less than 3 days. Similarly, when plasmid DNA was delivered in the absence of microbubbles and when ultrasound was applied, reporter gene expression did not reach our threshold of detection (data not shown). When microbubbles were diluted to 15% of the total 50 ml volume, gene transfer dramatically improved (Figure 2 ).
Gene expression dynamics with UAGT differ from viral-mediated gene transfer Figure 2 shows the average total flux (photons) for the region of interest (ROI) on days 1,3,7,14, 21 and 28 posttreatment for the various treatment groups. Figure 3 plots the total relative light unit of individual animals in the 15% microbubble/plasmid treatment group at various timepoints. This figure graphically illustrates our observation that UAGT to the salivary glands was robust and long lasting, but inconsistent. Whereas in two of six animals gene expression was undetectable after 1 day post-treatment, three of six animals in this treatment group showed sustained and robust gene expression.
Consistent with earlier reports, delivery of our reporter gene with an Ad vector resulted in a rapid and very high gene expression that dropped B100-fold within 10 days (Figure 2 ). This pattern was similar in both the high-(1 Â 10 9 viral particle (vp), n ¼ 4) and low-(1 Â 10 8 vp, n ¼ 4) dose groups. In contrast, UAGT (n ¼ 6 for 15% microbubbles, n ¼ 4 for 100% microbubbles) resulted in lower initial activity that intersected with the . Group sizes were as follows: n ¼ 4 for virus and 100% microbubble groups, n ¼ 6 for 15% microbubble group.
Ultrasound-assisted gene transfer to the salivary glands MJ Passineau et al viral-mediated treatment within 14 days. Gene expression with UAGT was sustained at constant levels through the 28-day endpoint of this study.
Spatial distribution of vector and transgene expression within the salivary gland is diffuse
Earlier reports have documented differential cellular tropism of Ad and Adeno-associated virus vectors for specific cellular substrates in the salivary gland. 20 We hypothesized that such cellular tropism would not be manifest when using ultrasound as a physical method of gene transfer. Further, the spatial distribution of the vector within the salivary gland following retrograde infusion has never been directly observed. The unique nature of our microbubble vector system allowed us to dynamically explore the distribution of the vector carrier solution during retroductal infusion using real-time ultrasonography. Figure 4a shows time-lapse ultrasonography of the salivary ductal labyrinth as microbubbles are injected, and it can be observed that the echoabsorbative (dark) signal quickly fills the entire anatomical space of the gland.
Having established a relatively even distribution of the vector within the gland, we then addressed the question of cell-specific tropism by performing immunohistochemistry against a green fluorescent protein (GFP) transgene in animals receiving 15% microbubbles+pCMV-GFP (a plasmid expressing green fluorescent protein under the control of the CMV promoter) versus 15% microbubbles alone. As shown in Figure 4b , GFP expression was quite modest, but in our hands seemed to be more strongly expressed in acinar cells with no detectable staining above the baseline in ductal cells. These differences were noted, but we interpret them cautiously, given the apparently very diffuse expression within the salivary gland. From a technical standpoint, it should be noted that histological analysis of reporter genes in the salivary gland is complicated both by endogenous b-galactosidase 21 and endogenous biotin, 22 and thus we have relied upon a less classical method of immunohistochemical localization. When these results are taken together with our in vivo Luc imaging, we see evidence that UAGT leads to diffuse gene transfer that is modest on a cell-to-cell basis but nevertheless in the aggregate, attains a magnitude of overall transgene expression similar to the more cell-specific viralmediated gene transfer (as has been shown in Figure 2 ).
UAGT does not cause substantial salivary gland inflammation or morphological disruption
In consideration of earlier studies which have documented extensive inflammation and presumably consequent loss of gene expression in tissues treated with Ad-mediated gene transfer, 20, 23 we examined sialoadenitis in a second cohort of animals (n ¼ 3) seven days after gene delivery with Ad vectors or UAGT. Results are presented in Figure 5 , which presents the average degree of sialoadenitis in the various treatment groups on the basis of the criteria described elsewhere. 24 As expected, we saw modest inflammation at a high vector dose (5 Â 10 9 vp, n ¼ 3). However, a lower viral vector dose (1 Â 10 8 vp, n ¼ 4) and UAGT did not differ substantially from untreated animals (n ¼ 4). We therefore conclude that UAGT does not elicit substantial inflammation or overt morphological changes in the salivary gland.
Discussion
Our findings show the initial feasibility of non-viral gene delivery and expression in the salivary gland using UAGT. Further, we have observed gene expression that remains relatively stable over the course of 4 weeks posttreatment and, although initially lower in magnitude than Ad-mediated gene transfer, intersects with Ad gene expression within 1-2 weeks depending on the initial viral vector dose. Whereas previous reports involving Ad-mediated gene transfer to the salivary glands have indicated a peak of transgene expression in the first week, followed by an extinction by week 2, 20 we have noted two phases of Ad-mediated expression with greatly reduced but sustained expression at day 28. We attribute this additional information to the sensitivity of our in vivo Luc imaging method and this observation forces us to confront the important question of whether the magnitude of gene expression we report with our UAGT technique is adequate for gene therapy applications. This question can only be addressed speculatively based on the present data, but we submit that future improvements may serve to enhance the magnitude of gene expression using UAGT.
It is important to note that previous reports of UAGT phenomena in vivo fall into two categories: (1) the gene delivery vector and microbubbles are sequestered within an anatomical space, after which ultrasound is applied; 25, 26 and (2) Ultrasound-assisted gene transfer to the salivary glands MJ Passineau et al microbubbles are injected systemically to disseminate through the intravascular space, after which ultrasound is directed at the target tissue (usually an organ). 27, 28 Our approach is in the former category as the intraductal volume of the salivary gland is encased within the capsule of connective tissue that encompasses the gland, sequestering our gene delivery and microbubbles. This schema allows more precise control of plasmid/ microbubble concentration and localization than is possible with the intravascular delivery of plasmid/ microbubbles.
As alluded to above, the concentration of infused microbubbles within the salivary gland is a critical variable governing the efficacy of our system. We speculate that this has to do with changes in the mechanical index of the ultrasound waves as they propagate through the region of the intraductal labyrinth containing high concentrations of microbubbles. It is reasonable to speculate that the relatively high air/fluid ratio in the intraductal space in our 100% microbubble infusion may partially quench the ultrasound wave, rendering it less effective in destroying microbubbles, leading to the paradoxical effect that more microbubbles result in less gene transfer. We suggest that perhaps this issue of local concentration of microbubbles in an ultrasound-near field may partially explain the sometimes inconsistent reproducibility of UAGT in vivo, which has hampered progress in this research area.
The morphological condition of the salivary gland following UAGT is an intriguing finding of this study. The only clinical trial to date involving gene transfer Ultrasound-assisted gene transfer to the salivary glands MJ Passineau et al to the salivary glands has used an Ad vector, which Baum and colleagues have shown to elicit substantial inflammation in the gland, 23, 29 presumably leading to functional impairment (which has been proposed to be mainly reversible 30 ). Our findings are in general agreement with earlier work in this field, indicating that transient physical disruption of cell membranes by local ultrasound-induced cavitation is not permanently injurious to the target cells. 31 For clinical applications requiring extended or lifelong gene expression, this is a critical consideration as cells comprising the salivary gland do not significantly regenerate and divide in the adult, and thus preservation of existing salivary gland parenchyma is a paramount consideration when re-dosing of gene therapy is necessary.
Practical application of this technology to the clinical practice of dental medicine will need to incorporate more sophisticated plasmid vectors to achieve a maximal interval between gene transfer 'boosters'. Firstgeneration plasmid vectors, such as the pGL3 plasmid, used in our experiments contain unmethylated C-phosphate-G (CpG) and other sequences of bacterial origin, which have been shown to trigger premature silencing of the episomal plasmid DNA. Advancements in plasmid gene transfer technologies such as CpGreduced 32 or 'minicircle' 33,34 gene transfer constructs have been shown to express for months after non-viral gene transfer. With non-viral gene transfer to the salivary glands now a practicable reality, perfecting the plasmid vector to allow gene expression for clinically-relevant durations, perhaps 6 months between boosters, is a paramount translational goal.
In consideration of the above, further studies are needed to define and optimize the pharmacodynamics of UAGT to the salivary glands by maximizing the duration of gene expression and serial re-dosing in a chronic treatment paradigm.
Methods
Microbubble/plasmid solution and viral vectors
Definity microbubbles were purchased as 2 ml injectable suspension and activated with a Vialmix device according to manufacturer's instructions (Lantheus Medical Imaging, North Billerica, MA, USA). Microbubbles were used for experiments within 30 min of their activation. A total of 50 mg of pCMV-GL3 (a GL3 Luc-expressing plasmid constructed by the insertion of a cytomegalovirus (CMV) promoter into the multiple cloning site of pGL3-basic, Promega, Madison, WI, USA) was mixed with 50 ml of microbubble solution, either 100 or 15% Definity solution v/v with phosphate-buffered saline.
For Ad-mediated gene transfer, a non-replicative Ad Serotype 5 vector, based on the Stratagene AdEasy system was created by cloning the GL3 sequence (from the Promega pGL3 Basic vector) into the multiple cloning site of the pShuttle-CMV vector (Stratagene, La Jolla, CA, USA). The shuttle vector was recombined into the AdEasy backbone, and the resultant vector, Ad-CMV-GL3 was upscaled and purified to a titer of B3.5 Â 10 12 vp ml À1 . Ad vectors were delivered in 50 ml of phosphate-buffered saline.
Animals and salivary gland catheterizations
Mice of the strain C57BL/6 were obtained from Jackson Labs (Bar Harbor, ME, USA) and maintained in pathogen-free conditions in the Allegheny-Singer Research Institute vivarium, with an access to standard chow and water ad libitum. Animal experiments and protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Allegheny-Singer Research Institute. Gene transfer to the salivary gland is accomplished as previously described by Voutetakis and colleagues. 4 Briefly, the animal was anesthetized and placed in a stereotactic frame allowing the mouth to be held open. The tongue was retracted and a thin plastic catheter was placed into the opening of the submandibular duct on one side, advanced B1 cm and held in place with superglue. 50 ml of vehicle solution carrying the gene transfer vector (virus or plasmid/microbubbles) was infused into the duct on one side via the catheter and the plunger was left in place for 10 min to allow the vector to contact the salivary epithelial cells. The catheter was then removed and the animal returned to its cage to awaken normally.
For ultrasound gene transfer experiments, the skin immediately overlying the salivary gland was treated with a depilatory agent, a commercial ultrasound gel was applied and an ultrasound emitter (SoniGene, VisualSoincs Inc., Toronto, Canada) was placed in direct contact with the skin overlying the gland. After the plasmid microbubble solution was infused, 4 Â 30-s bursts were applied at the following parameters: 1 MHz, 50% duty cycle and 2 W cm À2 , with 10 s between pulses. Following the four pulses, the emitter was withdrawn and the animal was allowed to rest for 10 min before the catheter was removed.
In vivo Luc imaging
The mice were injected intramuscularly with 1 ml per g of body weight of ketamine (20 g ml À1 )/xylazine (100 mg ml À1 ) mixed in the proportion of 3:2. After the mouse was anesthetized, the D-Luciferin substrate (XenoLight D-Luciferin Potassium Salt, Caliper Life Sciences, Hopkinton, MA, USA) was injected intraperitoneally, at a dose of (100 ml per 10 g body weight, stock 15 mg ml À1 ). The mice were then placed in a light-tight chamber, and images were generated over a 1-minute exposure using a cryogenically cooled charge-coupling device camera IVIS Lumina II (Caliper Life Sciences) to quantify photons spontaneously emitted by the animal. Images were pseudocolored using the Xenogen (Caliper Life Sciences, Hopkinton, MA, USA) software and overlayed on a black-and-white photograph of the animal generated with cabinet lighting. The visual output represents the number of photons emitted s À1 cm À2 as a pseudocolor image where the maximum is red and the minimum is purple.
Quantitation of gene transfer and statistical analysis
Images obtained from in vivo imaging were analyzed using the Living Image software (Caliper Life Sciences). Photons emitted from the salivary gland were quantified by defining a ROI over the anatomical position of the salivary gland. In most cases, this ROI was generated automatically by the software using 'Auto Contour ROI', and total flux (photons s À1 ) in the ROI was measured. In Ultrasound-assisted gene transfer to the salivary glands MJ Passineau et al cases where the software was unable to generate an auto ROI, or when no discernable signal was present, a circle with a diameter corresponding to B0.75 cm was placed over the anatomical position of the salivary gland and total flux was measured. We consistently found that B3 Â 10 4 was the background value in this system. However, values were tabulated as total flux, without a correction for background.
Histology
To explore any potential differences in sialoadenitis elicited by the two gene delivery methods in the acute setting, we performed gene transfer on a second cohort of animals using methods identical to those described above, with the exception that half of the animals in this cohort were females, with genders being evenly distributed between Ad and UAGT groups. Animals were killed after 7 days and salivary glands were removed, fixed, paraffin-embedded, microtome sectioned and stained with hematoxylin and eosin. A blinded oral pathologist (PCE) examined the slides and graded the degree of sialoadenitis on a 1 (normal) to 4 (severe, with complete destruction of acinar cells) scale on the basis of a modification of Isacsson et al.
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To explore the spatial distribution of both plasmid/ microbubble vectors and resultant transgene expression, we delivered pCMV-GFP, a plasmid expressing GFP, in the same manner as described above using a 15% microbubble carrier solution. Immediately before infusion of the plasmid/microbubble mixture and immediately thereafter, ultrasound images of the salivary gland were acquired on a VisualSonics Vevo 770 (VisualSonics Inc., Toronto, Ontario, Canada) with an RMV-704 scanhead running in B-mode at 40 MHz. After 7 days, animals were killed and salivary glands were removed, fixed and paraffin-embedded. Sections were probed with a fluorescein isothiocyanate-conjugated anti-GFP polyclonal antibody (Abcam, Cambridge, MA, USA).
